公司拟将认购事项的估计所得款项净额约63.39亿港元用于优化资本结构并支持公司的健康及可持续发 展。 地平线机器人-W(09660)发布公告，于2025年9月25日(交易时段后)，公司、现有股东及经办人订立配售 及认购协议，据此，(i)现有股东各自同意出售，而经办人各自同意担任现有股东的代理，并基于最大努 力促使承配人以每股配售股份9.99港元的配售价购买配售股份;及(ii)现有股东各自有条件同意认购，而 公司已有条件同意根据一般授权配发及发行认购股份予现有股东，价格相当于每股配售股份的配售价 9.99港元。配售价较股份于最后交易日在联交所所报收市价每股10.60港元折让约5.75%。 ...

Group 1 - The company Yunfeng Financial (00376) has completed a placement of shares on September 18, 2025, under the terms of the placement and subscription agreement [1] - A total of 191.3 million existing shares were successfully placed at a price of HKD 6.10 per share to no fewer than six subscribers, all of whom are independent third parties [1] - Following the completion of the subscription, the total amount raised from the subscription was approximately HKD 1.17 billion, with a net amount of approximately HKD 1.15 billion [1] Group 2 - After the completion of the placement and subscription, no subscriber has become a major shareholder of the company [1] - All conditions for the completion of the subscription have been met, leading to the issuance of 191.3 million subscription shares at the same price of HKD 6.10 per share on September 23, 2025 [1]

Core Viewpoint - 康诺亚-B (02162.HK) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 864 million for various purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing about 7.72% of the company's issued shares as of the announcement date [2]. - The subscription involves 19 million new shares, accounting for approximately 6.36% of the enlarged share capital post-placement and subscription [2]. - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from about 27.79% to approximately 25.16% of the enlarged issued share capital [2]. Group 2: Pricing and Financial Details - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10 [2]. - The total expected proceeds from the subscription are approximately HKD 864 million, with net proceeds estimated at around HKD 854 million [2]. Group 3: Use of Proceeds - The net proceeds are planned to be allocated as follows: approximately 35% for R&D expenses related to CM512, CM518D1, and other pipelines; about 30% for the commercialization of the drug Siplizumab; around 25% for capital expenditures on manufacturing and R&D facilities; and 10% for general corporate and operational purposes [2].

Core Viewpoint - 康诺亚-B (02162) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 854 million for various development and operational purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing approximately 7.72% of the company's issued shares as of the announcement date [2]. - The number of subscription shares is 19 million, accounting for about 6.36% of the expanded share capital post-placement and subscription [2]. - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10, 2025 [2]. Group 2: Use of Proceeds - The net proceeds from the subscription, estimated to be around HKD 854 million after deducting commissions and estimated expenses, will be allocated for: - Research and development expenses for CM512, CM518D1, and other pipeline projects [2]. - Commercialization of the drug Siplizumab [2]. - Capital expenditures for manufacturing and research facilities [2]. - General corporate and operational funding [2].